Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis
نویسندگان
چکیده
منابع مشابه
Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis
Factor XIII is one of the twelve coagulation factors and also known as a fibrin-stabilizing factor. In 2012, we encountered a male RA patient with hemorrhagic factor XIII deficiency who had been treated with tocilizumab for two years. There are few reports regarding the relationship between tocilizumab (a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R)) and factor XIII....
متن کاملCutaneous manifestations in patients with rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with different extra-articular manifestations. Among those extra-articular manifestations, there are significant cutaneous manifestations which may result in first admission to a dermatologist. In this article some specific and non-specific skin lesions of RA such as rheumatoid nodules, exacerbated nodules, rheumatoid vascu...
متن کاملHearing status in patients with rheumatoid arthritis
Background: Previous studies showed that one of the complications of rheumatoid arthritis disease was auditory disorder. The goal of the present study was to compare the auditory status in patients with rheumatoid arthritis and healthy individuals. Methods: In the present case-control study, 30 normal persons and 60 persons with rheumatoid arthritis with mean age of 46.72 and standard deviatio...
متن کاملMalignancy rates in patients with rheumatoid arthritis treated with tocilizumab
OBJECTIVE To analyse malignancy rates in patients with rheumatoid arthritis (RA) treated with tocilizumab. METHODS Patients who received tocilizumab or placebo+methotrexate/disease-modifying antirheumatic drugs in the double-blind phases of 5-phase three trials or who received at least 1 dose of tocilizumab in the long-term extension studies were analysed up to the 2 May 2012 cut-off date. Ma...
متن کاملTocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis.
SIR, Biologic agents are widely used for the treatment of RA in today’s treat-to-target era [1]. Although their safety and efficacy are acceptable, autoimmune adverse events associated with biologics have increasingly been reported. According to the BIOGEAS Study Group [2], vasculitis and SLE are the most frequent autoimmune diseases induced by biologics, and most reports were associated with a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLoS ONE
سال: 2013
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0069944